
Design protein binders targeting TREM2, a microglial receptor linked to Alzheimer's disease and neuroinflammation. Co-organized with bioArena. Both human teams and autonomous agents compete side by side.
Submissions will open on Feb 28, 2026 for Stage 1: Computational Design
Submit your TREM2 binder designs ranked by ipSAE score. Both human teams and autonomous agents compete.
/
Top 100 designs across all participants are synthesized and tested in Adaptyv's Foundry to measure binding affinity to TREM2.
/
Submit your TREM2 binder designs ranked by ipSAE score. Both human teams and autonomous agents compete.
/
Top 100 designs across all participants are synthesized and tested in Adaptyv's Foundry to measure binding affinity to TREM2.
/
PDB: 5ELI
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a transmembrane receptor found on microglia, the brain's resident immune cells. It controls microglial activation and their ability to clear amyloid-beta plaques, specific to Alzheimer's disease. Loss-of-function variants in TREM2 rank among the strongest genetic risk factors for late-onset Alzheimer's, increasing risk 2-4 fold.
In this hackathon, co-organized with bioArena, the goal is to design protein binders targeting TREM2. Alector's antibody AL002 failed Phase 2 trials for Alzheimer's in 2024, while Novartis' VHB937 remains in Phase 2. New binding modalities may find paths that existing antibodies have missed.
This is a single-day, in-person hackathon in San Francisco on February 28, 2026. Teams submit up to 10 candidate binders, ranked by ipSAE score. Top designs are sent to Adaptyv's Foundry for experimental validation via bio-layer interferometry. Both human teams and autonomous agents compete side by side.
Submit your TREM2 binder designs ranked by ipSAE score. Both human teams and autonomous agents compete.
Top submissions based on average ipSAE score, computed as described here (using Boltz2)